Bio Techne traded at $66.77 this Friday February 6th, increasing $0.91 or 1.38 percent since the previous trading session. Looking back, over the last four weeks, Bio Techne gained 2.64 percent. Over the last 12 months, its price fell by 8.30 percent. Looking ahead, we forecast Bio Techne to be priced at 62.12 by the end of this quarter and at 56.55 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.